News Novo Nordisk cuts GLP-1 prices for cash buyers Novo Nordisk has said it will offer diabetes therapy Ozempic at $499 per month for cash-paying customers in the US.
News Under pressure from Trump, Lilly hikes Mounjaro prices in UK Lilly has said it will raise the UK list price of its diabetes and obesity therapy Mounjaro to bring it into parity with other European markets.
News Novo Nordisk weakens again on interim results readout Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the first half of this year.
News Lilly trumpets heart health data with Mounjaro Eli Lilly has raised the stakes in its rivalry with Novo Nordisk on GLP-1 drugs for diabetes, with new data for Mounjaro on cardiovascular outcomes.
News Novo Nordisk slumps as it cuts sales forecast, names new CEO Novo Nordisk has a new CEO, facing an uphill battle to restore the fortunes of its US business as diabetes and obesity drugs come under pressure.
News 'Diabetes Barbie' launches with medtech accessories Barbie just took a step forward for inclusivity and representation with the launch of a doll with type 1 diabetes.
News Agios mulls early FDA filing for sickle cell therapy Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
